T1	p 26 33	therapy
T2	p 51 80	in congestive heart failure .
T3	p 239 328	patients with moderate to severe congestive heart failure . Seventeen patients on chronic
T4	p 394 413	flosequinan ( n = 9
T5	p 431 432	=
T6	p 1057 1064	therapy
T7	p 1169 1225	patients with moderate to severe chronic heart failure .
T8	i 6 50	Chronic vasodilator therapy with flosequinan
T9	i 143 154	flosequinan
T10	i 183 195	arterial and
T11	i 203 210	dilator
T12	i 343 351	diuretic
T13	i 387 407	either flosequinan (
T14	i 416 428	or placebo (
T15	i 580 589	two-month
T16	i 630 637	therapy
T17	i 853 864	flosequinan
T18	i 1037 1112	chronic vasodilator therapy with flosequinan to standard digitalis-diuretic
T19	o 476 545	symptomatology , exercise performance , and left ventricular function
T20	o 664 697	the symptom scores and functional
T21	o 764 775	Flosequinan
T22	o 809 834	maximal exercise capacity
T23	o 896 916	progressive increase
T24	o 920 940	resting heart rate ,
T25	o 973 1020	indices of left ventricular systolic function .
T26	o 1145 1153	clinical
T27	o 1368 1405	clinical improvement , subpopulations